Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.

• 影响指数: 8.615
• 发表时间: 04 2021
• 来源期刊: Br J Haematol
• DOI: 10.1111/bjh.16656
• PMID: 32337716
• 文章类型: Journal Article
• 中科院分区: Q1
• 方向: 医学
• 作者列表: Aoki T,Takahashi H,Tanaka S,Shiba N,Hasegawa D,Iwamoto S,Terui K,Moritake H,Nakayama H,Shimada A,Koh K,Goto H,Kosaka Y,Saito AM,Horibe K,Kinoshita A,Tawa A,Taga T,Adachi S,Tomizawa D

关键词: acute myeloid leukaemia; chemosensitivity; children; myelosuppression; neutropenia

Mesh: Antineoplastic Combined Chemotherapy Protocols / adverse effects therapeutic use; Bone Marrow Failure Disorders / chemically induced; Child; Disease Susceptibility; Female; Granulocyte Colony-Stimulating Factor / adverse effects pharmacology; Humans; Japan / epidemiology; Leukemia, Myeloid, Acute / drug therapy immunology mortality; Male; Neutropenia / chemically induced epidemiology; Prognosis; Survival Analysis

Abstract

The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.